Aurobindo Pharma shares surge nearly 2.5% after the company signs Letter Of Intent with Merck & Dohme for contract manufacturing operations.
The pharmaceutical firm stated that its wholly-owned subsidiary, CuraTeQ Biologics Private Limited, in collaboration with its subsidiaries, has been engaged in talks with Merck Sharp & Dohme Singapore Trading Pte. Ltd. and its affiliated companies regarding Contract Manufacturing Operations (CMO).
On the final trading day, Aurobindo Pharma initiated at ₹901.5 and concluded at ₹900.95. Throughout the day, the stock attained a peak of ₹908.75 and dipped to a low of ₹895.3. Aurobindo Pharma’s market capitalization stands at ₹52,713.97 crore. Over the past 52 weeks, the stock has ranged from a high of ₹930 to a low of ₹397.3. The BSE volume recorded for the day amounted to 28,929 shares.
At the time of reporting the shares of the company were trading 2.12% up at ₹918.95
